Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral semaglutide monotherapy delivers HbA1c improvements in type 2 diabetes

Key clinical point: Oral semaglutide monotherapy significantly reduced HbA1c in patients with type 2 diabetes, compared with placebo in patients managed by diet and exercise alone.

Major finding: At 26 weeks, the differences in HbA1c for medication daily doses of 3 mg, 7 mg, and 14 mg using an intention-to-treat analysis, were –0.6%, –0.9%, and –1.1%, respectively (P less than .001 for all).

Study details: A randomized, double-blind, placebo-controlled, multicenter trial of 703 adults with type 2 diabetes.

Disclosures: Novo Nordisk funded the study. The lead author disclosed relationships with Novo Nordisk, and several coauthors disclosed relationships with or employment by the company.


Aroda VR et al. Diabetes Care. 2019 Jul. doi: 10.2337/dc19-0749.